Overview
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
Status:
Recruiting
Recruiting
Trial end date:
2023-06-01
2023-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapyPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Handok Inc.Treatments:
Amlodipine
Irbesartan
Criteria
Inclusion Criteria:- Patients who are 19 years or older on screening
- Signed informed consent
- Patients with Essential Hypertension
- Other inclusion applied
Exclusion Criteria:
- Orthostatic hypotension with symptom
- Other exclusion applied